134 related articles for article (PubMed ID: 22568397)
1. Use of 131 I-MIBG therapy in MIBG-positive metastatic medullary thyroid carcinoma.
Maiza JC; Grunenwald S; Otal P; Vezzosi D; Bennet A; Caron P
Thyroid; 2012 Jun; 22(6):654-5. PubMed ID: 22568397
[No Abstract] [Full Text] [Related]
2. Detection of medullary carcinoma of the thyroid with I-131 MIBG.
Thomas CC; Cowan RJ; Albertson DA; Cooper MR
Clin Nucl Med; 1994 Dec; 19(12):1066-8. PubMed ID: 7874804
[TBL] [Abstract][Full Text] [Related]
3. Metastatic medullary thyroid cancer: localization with iodine-131 metaiodobenzylguanidine.
Sone T; Fukunaga M; Otsuka N; Morita R; Muranaka A; Yanagimoto S; Tomomitsu T; Nakayama H; Harada T
J Nucl Med; 1985 Jun; 26(6):604-8. PubMed ID: 3158726
[TBL] [Abstract][Full Text] [Related]
4. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG].
Mukherjee JJ; Kaltsas GA; Islam N; Plowman PN; Foley R; Hikmat J; Britton KE; Jenkins PJ; Chew SL; Monson JP; Besser GM; Grossman AB
Clin Endocrinol (Oxf); 2001 Jul; 55(1):47-60. PubMed ID: 11453952
[TBL] [Abstract][Full Text] [Related]
5. Intraarterial 131I-MIBG therapy of neuroendocrine tumors with liver metastases.
Popp M; Strumpf A; Zöphel K; Stroszczynski C; Kotzerke J
Nuklearmedizin; 2010; 49(1):N2-3. PubMed ID: 20336828
[No Abstract] [Full Text] [Related]
6. Differentiated thyroid carcinoma after 131I-MIBG treatment for neuroblastoma during childhood: description of the first two cases.
van Santen HM; Tytgat GA; van de Wetering MD; van Eck-Smit BL; Hopman SM; van der Steeg AF; Nieveen van Dijkum EJ; van Trotsenburg AS
Thyroid; 2012 Jun; 22(6):643-6. PubMed ID: 22524499
[TBL] [Abstract][Full Text] [Related]
7. Dosimetry in nuclear medicine therapy: what are the specifics in image quantification for dosimetry?
Bardiès M; Buvat I
Q J Nucl Med Mol Imaging; 2011 Feb; 55(1):5-20. PubMed ID: 21386782
[No Abstract] [Full Text] [Related]
8. [Incidental detection of a papillary thyroid cancer by ¹⁸F-FDG PET-CT study in a patient with metastatic colorectal cancer].
Banzo J; Ubieto MA; Villalta J; Razola P; Prats E; Andrés A
Rev Esp Med Nucl; 2010; 29(6):312-3. PubMed ID: 20826040
[No Abstract] [Full Text] [Related]
9. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.
Kaltsas G; Korbonits M; Heintz E; Mukherjee JJ; Jenkins PJ; Chew SL; Reznek R; Monson JP; Besser GM; Foley R; Britton KE; Grossman AB
J Clin Endocrinol Metab; 2001 Feb; 86(2):895-902. PubMed ID: 11158063
[TBL] [Abstract][Full Text] [Related]
10. Scintigraphy and treatment of medullary carcinoma of the thyroid with iodine-131 metaiodobenzylguanidine.
Clarke SE; Lazarus CR; Edwards S; Murby B; Clarke DG; Roden TM; Fogelman I; Maisey MN
J Nucl Med; 1987 Dec; 28(12):1820-5. PubMed ID: 3681441
[TBL] [Abstract][Full Text] [Related]
11. [Long-term follow-up of a case of thyroid medullary carcinoma spreading to lung and liver].
Zharinov GM; Malysheva LG; Neklasova NIu; Polysalov VN; Urbanskiĭ AI; Tarkova AB
Vopr Onkol; 2011; 57(3):378-81. PubMed ID: 21882612
[No Abstract] [Full Text] [Related]
12. [The evaluation of 123I-MIBG scintigraphy in medullary thyroid carcinoma (MTC)].
Ahuja S; Koppenhagen K; Ernst H
Strahlenther Onkol; 1990 Nov; 166(11):718-21. PubMed ID: 2260009
[TBL] [Abstract][Full Text] [Related]
13. [Nuclear medicine diagnosis and therapy of distant metastases of pheochromocytoma].
Grünwald F; Ruhlmann J; Kozak B; Overlack A; Christ F; Hotze A; Biersack HJ
Dtsch Med Wochenschr; 1988 Feb; 113(8):297-9. PubMed ID: 3277832
[TBL] [Abstract][Full Text] [Related]
14. Imaging of metastatic medullary carcinoma of the thyroid with 131I-meta-iodobenzyl guanidine.
Poston GJ; Thomas AM; Macdonald DW; Karvounaris D; Henderson BL; George P; Lynn JA; Lavender JP
Nucl Med Commun; 1986 Apr; 7(4):215-21. PubMed ID: 2873544
[TBL] [Abstract][Full Text] [Related]
15. Multistage high-dose I-131 treatment for a nonthyroidectomized patient with metastatic differentiated thyroid cancer.
Ahn BC; Lee SW; Lee J
Clin Nucl Med; 2011 Dec; 36(12):e224-7. PubMed ID: 22064117
[No Abstract] [Full Text] [Related]
16. Localization of hepatic metastases by radiolabelled anti-carcinoembryonic antigen antibody and meta-iodobenzylguanidine in a patient with medullary thyroid carcinoma.
Liewendahl K; Välimäki M; Taavitsainen M
Eur J Nucl Med; 1993 Jun; 20(6):551-4. PubMed ID: 8339736
[TBL] [Abstract][Full Text] [Related]
17. PET imaging of recurrent medullary thyroid cancer.
Simon GH; Nitzsche EU; Laubenberger JJ; Einert A; Moser E
Nuklearmedizin; 1996 Jun; 35(3):102-4. PubMed ID: 8710526
[TBL] [Abstract][Full Text] [Related]
18. [Therapeutic advances of nuclear medicine in oncology].
Valdés Olmos RA; Hoefnagel CA; Bais E; Boot H; Taal B; de Kraker J; Vote PA
Rev Esp Med Nucl; 2001 Dec; 20(7):547-57. PubMed ID: 11709141
[TBL] [Abstract][Full Text] [Related]
19. Radioiodinated metaiodobenzylguanidine treatment of neuroendocrine tumors in adults.
Postema EJ; McEwan AJ
Cancer Biother Radiopharm; 2009 Oct; 24(5):519-25. PubMed ID: 19877881
[TBL] [Abstract][Full Text] [Related]
20. [Internal radiation therapy for malignant neoplasm].
Yokoyama K; Kinuya S; Tonami N
Gan To Kagaku Ryoho; 1999 May; 26(6):768-74. PubMed ID: 10410145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
